Definition Oclacitinib is a small-molecule pharmaceutical compound classified as a Janus kinase (JAK) inhibitor, specifically targeting JAK1 with selectivity over other JAK family members. It is primarily used in veterinary medicine.
Overview Oclacitinib is approved for the treatment of pruritus (itching) associated with allergic dermatitis and atopic dermatitis in dogs. It functions by modulating signaling pathways involved in inflammation and immune responses, particularly those mediated by cytokines that depend on JAK1 for intracellular signal transduction. Marketed under the brand name Apoquel by Zoetis, it was conditionally approved by the U.S. Food and Drug Administration (FDA) for veterinary use in 2013 and subsequently fully approved.
The drug is administered orally and is indicated for dogs over 12 months of age. Clinical trials have demonstrated its efficacy in reducing pruritus within 24 hours of administration. Common adverse effects observed in clinical studies include vomiting, diarrhea, anorexia, and potential susceptibility to infections due to immunomodulation.
Etymology/Origin The term "Oclacitinib" follows the standard nomenclature for pharmaceutical substances, particularly kinase inhibitors, which commonly use the suffix "-itinib" to denote inhibitors of tyrosine kinases. The prefix "ocla-" does not correspond to a publicly documented etymological root and may be a proprietary designation selected by the manufacturer during drug development. Accurate information regarding the specific origin of the name is not confirmed.
Characteristics
- Chemical Classification: Small molecule, Janus kinase (JAK) inhibitor
- Primary Target: JAK1 (with functional selectivity)
- Pharmacological Use: Anti-inflammatory, antipruritic (in veterinary medicine)
- Administration Route: Oral
- Species Indicated: Canines (dogs)
- Regulatory Status: FDA-approved for veterinary use in the United States
- Metabolism: Primarily hepatic, via cytochrome P450 enzymes
- Elimination: Renal and fecal excretion
Related Topics
- Janus kinase inhibitors
- Atopic dermatitis in animals
- Veterinary immunopharmacology
- Apoquel (brand name)
- Cytokine signaling
- Allergic skin disease in dogs
- JAK-STAT signaling pathway
Note: Oclacitinib is not approved for use in humans, and its safety and efficacy profile is established within the context of canine therapeutics.